Summary
Non-insulin-dependent diabetes mellitus (NIDDM) is a strong and independent risk factor for coronary heart disease. We assessed the potential relationship between plasma Lp(a) levels, apo(a) phenotypes and coronary heart disease in a population of NIDDM patients. Seventy-one patients with coronary heart disease, who previously have had transmural myocardial infarction, or significant stenosis on coronary angiography, or positive myocardial thallium scintigraphy, or in combination, were compared with 67 patients without coronary heart disease, who tested negatively upon either coronary angiography, myocardial thallium scintigraphy or a maximal exercise test. The prevalence of plasma Lp(a) levels elevated above the threshold for increased cardiovascular risk (>0.30 g/l) was significantly higher (p=0.005) in patients with coronary heart disease (33.8%) compared to the control group (13.4%). The relative risk (odds ratio) of coronary heart disease among patients with high Lp(a) concentrations was 3.1 (95% confidence interval, 1.31–7.34;p=0.01). The overall frequency distribution of apo(a) phenotypes differed significantly between the two groups (p=0.043). However, the frequency of apo(a) isoforms of low apparent molecular mass (≤700 kDa) was of borderline significance (p=0.067) between patients with or without coronary heart disease (29.6% and 16.4%, respectively). In this Caucasian population of NIDDM patients, elevated Lp(a) levels were associated with coronary heart disease, an association which was partially accounted for by the higher frequency of apo(a) isoforms of small size. In multivariate analyses, elevated levels of Lp(a) were independently associated with coronary heart disease (odds ratio 3.48, p=0.0233).
Article PDF
Similar content being viewed by others
Abbreviations
- NIDDM:
-
Non-insulin-dependent diabetes mellitus
- IDDM:
-
insulin-dependent diabetes mellitus
- CHD:
-
coronary heart disease
- Lp(a):
-
lipoprotein(a)
- apo(a):
-
apolipoprotein(a)
- apoB:
-
apolipoprotein B
- HMGCoA reductase:
-
hydroxymethylglutaryl coenzyme A reductase
References
Stamler J, Vaccaro O, Neaton JD, Wentworth D, Group MR (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16: 434–444
Assmann G, Schutle H (1988) The Prospective Cardiovascular Münster (PROCAM) Study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 116: 1713–1724
Kannel WB, Mc Gee DL (1979) Diabetes and cardiovascular risk factors. The Framingham study. Circulation 59: 8–13
Mc Lean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM (1987) cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330: 132–137
Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH (1991) Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulse-field gel electrophoresis. J Clin Invest 87: 2153–2161
Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C (1987) Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 80: 458–465
Boerwinkle E, Menzel HJ, Kraft HG, Utermann G (1989) Genetics of the quantitative Lp(a) lipoprotein trait. Contribution of Lp(a) glycoprotein phenotypes to normal lipid values. Hum Genet 82: 73–78
Scanu AM, Fless GM (1990) Lipoprotein(a). Heterogeneity and biological relevance. J Clin Invest 85: 1709–1715
Genest J, Jenner JL, McNamara JR et al. (1991) Prevalence of lipoprotein(a) (Lp(a)) excess in coronary artery disease. Am J Cardiol 67: 1039–1045
Sandholzer C, Boerwinkle E, Saha N, Tong MC, Utermann G (1992) Apolipoprotein(a) phenotype, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of apo(a) gene in coronary heart disease. J Clin Invest 89: 1040–1046
Sandholzer C, Saha N, Kark JD et al. (1992) Apo(a) isoforms predict risk for coronary heart disease: a study of six populations. Arterioscler Thromb 12: 1214–1226
Haffner SM, Morales PA, Stern MP, Gruber MK (1992) Lp(a) concentrations in NIDDM. Diabetes 41: 1267–1272
Császár A, Dieplinger H, Sandholzer C et al. (1993) Plasma lipoprotein(a) concentration and phenotypes in diabetes mellitus. Diabetologia 36: 47–51
Niskanen L, Mykkänen L, Karonen SL, Uusitupa M (1993) Apoprotein(a) levels in relation to coronary heart disease and risk factors in type 2 (non-insulin-dependent) diabetes. Cardiovascular Risk Factors 3: 76–81
Heller FG, Jamart J, Honore P et al. (1993) Serum lipoprotein(a) in patients with diabetes mellitus. Diabetes Care 16: 819–823
Velho G, Erlich D, Turpin E et al. (1993) Lipoprotein(a) in diabetic patients and normoglycemic relatives in familial NIDDM. Diabetes Care 16: 742–747
Nesto RW, Philipps RT (1986) Asymptomatic myocardial ischemia in diabetic patients. Am J Med 80 [Suppl 4 C]: 40–47
Naka M, Hiramatsu K, Aizawa T et al. (1992) Silent myocardial ischemia in patients with non-insulin-dependent diabetes mellitus as judged by treadmill exercise testing and coronary angiography. Am Heart J 23: 46–52
Nesto RW, Philipps RT, Kett KG et al. (1988) Angina and exertional ischemia in diabetic and nondiabetic patients: assessment by exercise thallium scintigraphy. Ann Intern Med 108: 170–175
WHO Study Group (1985) Diabetes mellitus. World Health Organisation, Tech Rep Ser no. 727, Geneva
Thillet J, Faucher C, Issad B, Allouache M, Chapman J, Jacobs C (1993) Lipoprotein(a) in patients treated by continuous ambulatory peritoneal dialysis. Am J Kidney Dis 22: 226–232
Guo HC, Armstrong VW, Luc G et al. (1989) Characterization of five mouse monoclonal antibodies to apolipoprotein(a) from human Lp(a): evidence for weak plasminogen reactivity. J Lipid Res 30: 23–37
Kamboh MI, Ferrell RE, Kottke BA (1991) Expressed hypervariable polymorphism of apolipoprotein(a). Am J Hum Genet 49: 1063–1074
Bronstein I, Voyta JC, Murphy OJ, Bresnick L, Kricka LJ (1992) Improved chemiluminescent Western blotting procedure. Biotechniques 12: 748–753
Dahlén GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM (1986) Association of levels of lipoprotein Lp(a), plasma lipids and other lipoproteins with coronary artery disease documented by angiography. Circulation 74: 758–765
Cressmann MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF (1992) Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86: 475–482
Carlson LA, Hamsten A, Asplund A (1989) Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid. J Int Med 226: 271–276
Keilani T, Schlueter WA, Levin ML, Batlle DC (1993) Improvement of lipid abnormalities associated with proteinuria using Fosinopril, an angiotensin-converting enzyme inhibitor. Ann Intern Med 118: 246–254
Hervio L, Chapman MJ, Thillet J, Loyau S, Anglés-Cano E (1993) Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis? Blood 82: 392–397
Cohen JC, Chiesa J, Hobbs H (1993) Sequence polymorphisms in the apolipoprotein(a) gene: evidence of dissociation between apolipoprotein(a) size and plasma lipoprotein(a) levels. J Clin Invest 91: 1630–1636
Soma M, Fumagalli R, Paoletti R et al. (1991) Plasma Lp(a) concentration after oestrogen and progestagen in postmenauposal women. Lancet 337: 612
Parra HJ, Mezdour H, Cachera C, Dracon M, Tacquet A, Fruchart JC (1987) Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem 33: 721
Jenkins AJ, Steele JS, Janus E-D, Santamaria JD, Best JD (1992) Plasma apolipoprotein(a) is increased in type 2 (noninsulin-dependent) diabetic patients with microalbuminuria. Diabetologia 35: 1055–1059
Nielsen FS, Voldsgaard AI, Gall MA et al. (1993) Apolipoprotein(a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy. Diabetologia 36: 438–444
Haffner SM, Morales PA, Gruber MK, Hazuda HP, Stern MP (1993) Lack of association of lipids, lipoproteins and Lp(a) with microalbuminuria in NIDDM. Arteriosclerosis 13: 205–210
Mattock MB, Keen H, Viberti GC et al. (1988) Coronary heart disease and urinary albumin excretion rate in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 31: 82–87
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ruiz, J., Thillet, J., Huby, T. et al. Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes. Diabetologia 37, 585–591 (1994). https://doi.org/10.1007/BF00403377
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00403377